163 related articles for article (PubMed ID: 37198099)
1. The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence.
Das S; Gu L; Eve CT; Parrish J; De Hoedt AM; McKee C; Aronson W; Freedland SJ; Williams SB
Clin Genitourin Cancer; 2023 Dec; 21(6):711.e1-711.e6. PubMed ID: 37198099
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Shore ND; Gavaghan MB
Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
[TBL] [Abstract][Full Text] [Related]
3. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
4. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
Chappidi MR; Yang H; Meng MV; Bivalacqua TJ; Daneshmand S; Holzbeierlein JM; Kaimakliotis HZ; Konety B; Liao JC; Pohar K; Steinberg GD; Taylor JM; Tyson MD; Willard B; Lotan Y; Porten SP; Kates M
J Urol; 2022 Mar; 207(3):534-540. PubMed ID: 34694916
[TBL] [Abstract][Full Text] [Related]
5. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
6. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
Daneshmand S; Bazargani ST; Bivalacqua TJ; Holzbeierlein JM; Willard B; Taylor JM; Liao JC; Pohar K; Tierney J; Konety B;
Urol Oncol; 2018 Aug; 36(8):361.e1-361.e6. PubMed ID: 29859728
[TBL] [Abstract][Full Text] [Related]
7. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
Pietzak EJ
Curr Urol Rep; 2017 May; 18(5):39. PubMed ID: 28324275
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
[TBL] [Abstract][Full Text] [Related]
10. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.
Soorojebally Y; Neuzillet Y; Lebret T; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Lamy PJ; Oudard S; Rébillard X; Roy C; Roumiguié M; Rouprêt M; Audenet F
Prog Urol; 2023 May; 33(6):307-318. PubMed ID: 37088584
[TBL] [Abstract][Full Text] [Related]
12. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
Yang LP
Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555
[TBL] [Abstract][Full Text] [Related]
13. HAL fluorescence cystoscopy and TURB one year of Romanian experience.
Geavlete B; Mulţescu R; Georgescu D; Jecu M; Geavlete P
J Med Life; 2009; 2(2):185-90. PubMed ID: 20108538
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Diagnosis of Urothelial Bladder Cancer with Blue Light Cystoscopy via Recognition of False-Positive Lesions.
Bazargani ST; Djaladat H; Schuckman AK; Hugen CM; Daneshmand S
Videourology (New Rochelle); 2018; 32(2):. PubMed ID: 31976152
[No Abstract] [Full Text] [Related]
15. Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Zhao H; Peng P; Luo Z; Liu H; Sun J; Wang X; Jia Q; Yang Z
Photodiagnosis Photodyn Ther; 2023 Mar; 41():103220. PubMed ID: 36462704
[TBL] [Abstract][Full Text] [Related]
16. A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study.
Lapini A; Minervini A; Masala A; Schips L; Pycha A; Cindolo L; Giannella R; Martini T; Vittori G; Zani D; Bellomo F; Cosciani Cunico S
Surg Endosc; 2012 Dec; 26(12):3634-41. PubMed ID: 22729704
[TBL] [Abstract][Full Text] [Related]
17. Hexvix blue light fluorescence cystoscopy--a promising approach in diagnosis of superficial bladder tumors.
Geavlete B; Mulţescu R; Georgescu D; Geavlete P
J Med Life; 2008; 1(3):355-62. PubMed ID: 20108513
[TBL] [Abstract][Full Text] [Related]
18. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
[TBL] [Abstract][Full Text] [Related]
19. The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
Lawler C; Gu L; Howard LE; Branche B; Wiggins E; Srinivasan A; Foster ML; Klaassen Z; De Hoedt AM; Gingrich JR; Theodorescu D; Freedland SJ; Williams SB
Cancer; 2021 Nov; 127(21):3998-4005. PubMed ID: 34237155
[TBL] [Abstract][Full Text] [Related]
20. [Hexvix induced fluorescence blue light cystoscopy--a new perspective in superficial bladder tumors diagnosis].
Geavlete B; Mulţescu R; Georgescu D; Geavlete P
Chirurgia (Bucur); 2008; 103(5):559-64. PubMed ID: 19260632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
